

General Information	
Name of the Company*	Samrat Pharmachem Limited
NSE Symbol*	NOTLISTED
BSE Scrip Code*	530125
MSEI Symbol*	NOTLISTED
ISIN*	INE103E01016
Type of Announcement*	New
Type of Event*	Issue of duplicate share certificates/Letter of Confirmation
Details of other event	
Date of original announcement	
Remarks (website dissemination)	
Remarks for Exchange (not for Website Dissemination)	
Date of Report	19-06-2026

Issue of Duplicate Share Certificates/Letter of Confirmation											
Number of shareholders to whom duplicate share certificate/Letter of Confirmation has been issued*							1				
Details of Shareholders to whom duplicate share certificate/Letter of Confirmation has been issued											
Date of receipt of information for issue of duplicate share certificate/Letter of Confirmation*	Name*	Folio Number	Number of Shares	Old Certificate Number		New Certificate/Letter of Confirmation Number		Distinctive Number		Reason for issue of duplicate share certificate/Letter of Confirmation	Non-Compliance trigger
				From	To	From	To	From	To		
18-06-2026	SANGEETA H PAREKH, HITESH C PAREKH	0014052	2700	11533	11559	31010	31010	1153201	1155900	ORIGINAL LOST	
18-06-2026	SANGEETA H PAREKH, HITESH C PAREKH	0014052	200	12226	12227	31010	31010	1222501	1222700	ORIGINAL LOST	
18-06-2026	SANGEETA H PAREKH, HITESH C PAREKH	0014052	200	14461	14462	31010	31010	1446001	1446200	ORIGINAL LOST	
18-06-2026	SANGEETA H PAREKH, HITESH C PAREKH	0014052	200	14570	14571	31010	31010	1456901	1457100	ORIGINAL LOST	
18-06-2026	SANGEETA H PAREKH, HITESH C PAREKH	0014052	100	18088	18088	31010	31010	1808701	1808800	ORIGINAL LOST	
18-06-2026	SANGEETA H PAREKH, HITESH C PAREKH	0014052	100	20877	20877	31010	31010	2087601	2087700	ORIGINAL LOST	
Name of Registrar and Transfer Agent (RTA) of the Company*							Others				
Name of other RTA							MUFG Intime India Private Limited				
Whether the Company has complied with Regulation 39 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015*							Yes				
If No, specify the reason											
Any other disclosure w.r.t. compliance of any SEBI Act, Regulation, Circular or provision											
Any other information											
Remarks (website dissemination)											
Remarks for Exchange (not for Website dissemination)											

SAMRAT PHARMACHEM LIMITED

REGISTER OF NEW SHARE CERTIFICATES ISSUED ON DUPLICATION

FROM : TN60 TO :- TN60

Tr.no /Appr.Dt	FOLIO NO. SHAREHOLDER'S NAME	CERT.NO		DIST.NOS		SHARES	PAID VALUE	STUS	Deno	Cert Type	MICR From	MICR To
		FROM	TO	FROM	TO							
TN60 18/06/2026	0014052 SANGEETA H PAREKH HITESH C PAREKH	11533	11559	1153201	1155900	2700 OLD	10	DUP	2700			
		12226	12227	1222501	1222700	200 OLD	10		200			
		14461	14462	1446001	1446200	200 OLD	10		200			
		14570	14571	1456901	1457100	200 OLD	10		200			
		18088	18088	1808701	1808800	100 OLD	10		100			
		20877	20877	2087601	2087700	100 OLD	10		100			

						3500						
		31010	31010	1153201	1155900	2700 NEW	10		2700			
		31010	31010	1222501	1222700	200 NEW	10		200			
		31010	31010	1446001	1446200	200 NEW	10		200			
		31010	31010	1456901	1457100	200 NEW	10		200			
		31010	31010	1808701	1808800	100 NEW	10		100			
		31010	31010	2087601	2087700	100 NEW	10		100			

						3500						

SAMRAT PHARMACHEM LIMITED

REGISTER OF NEW SHARE CERTIFICATES ISSUED ON DUPLICATION

FROM : TN60 TO :- TN60

***** BATCH CONTROLS*****

1. TOTAL NO.OF REQUESTS	:	1
2. TOTAL NO.OF OLD CERTIFICATES	:	35
3. TOTAL NO.OF NEW CERTIFICATES	:	1
4. TOTAL NO.OF PAGES	:	2

***** CERTIFICATE (S)CONTROLS*****

5. TOTAL NO.OF DUPLICATED CERTIFICATE	:	6
6. TOTAL NO.OF DUPLICATED SHARES	:	3500
7. TOTAL NO.OF SUB DIVIDED CERTIFICATE	:	0
8. TOTAL NO.OF SUB DIVIDED SHARES	:	0
9. TOTAL NO.OF CONSOLIDATED CERTIFICATE	:	0
10. TOTAL NO.OF CONSOLIDATED SHARES	:	0

Samrat Pharmachem Limited

From: contact@samratpharmachem.in
Sent: 18 June 2026 14:10
To: 'Manav Sharma'
Cc: 'Dilip Rajpurohit'; 'Samrat Pharmachem Limited'
Subject: RE: Approval pending - Samrat Pharmachem Limited

Approval Date: 18-06-2026

From: Manav Sharma <manav.sharma@in.mpms.mufig.com>
Sent: Thursday, 18 June, 2026 11:08 AM
To: contact@samratpharmachem.in
Cc: Dilip Rajpurohit <dilip.rajpurohit@in.mpms.mufig.com>
Subject: FW: Approval pending - Samrat Pharmachem Limited

Dear Sir/Madam,

The below mentioned DU1327 case is in TAT and has to be closed by 19/06/2026.

Inward Certificate No.	Inward Certificate Date	Seller Folio	Seller Name	Buyer Folio No	Pending
DU1327	22/05/2026	0014052	SANGEETA H PAREKH	0014052	28

Kindly provide the approval date at the earliest to proceed further.

Thanks & Regards

Manav Sharma
Associate – Client Relations



MUFG Intime India Private Limited

A part of MUFG Corporate Markets, a division of MUFG Pension & Market Services
(Formerly Link Intime India Private Limited)

C-101, Embassy 247, L.B.S. Marg, Vikhroli (West), Mumbai – 400 083.

www.in.mpms.mufg.com | Follow us: [LinkedIn](#)

T: +91 22 4918 6000 (2328)

manav.sharma@in.mpms.mufg.com



Do you really need to print this email?

DISCLAIMER: This email (which includes any attachments or links to other websites) is intended solely for the named addressee. It is confidential and may contain legally privileged information. Delivery to any person other than the named addressee does not waive privilege or confidentiality. If you have received this email in error, let us know by reply email, delete it from your system and destroy any copies. This email is also subject to copyright. You must not reproduce or distribute it without our consent. We believe that information contained in this email is correct but we give no warranty as to its accuracy or completeness. It is provided as general information only and does not take into account your particular circumstances. It does not purport to be investment advice and you must not act in reliance on it. To the extent permitted by law, we disclaim all liability (including liability for negligence) for direct or indirect loss or damage suffered by any recipient acting in reliance on this email. This email may contain information or links to websites prepared by people who are not our employees or representatives. Such information will be identified as the product of an independent third party. It is provided for your interest and convenience only. We have not independently verified (and to the extent permitted by law disclaim all liability for) its accuracy or completeness and it does not constitute our recommendation or opinion. Emails may be interfered with, may contain computer viruses or other defects and may not be successfully replicated on other systems. It is the responsibility of the recipient to verify the integrity and authenticity of this email and to ensure that any attachments are scanned for viruses.